Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 473,980 | 598,028 | 431,399 | 354,864 | 348,234 |
| Marketable Securities | 908,815 | 797,940 | 825,700 | 372,912 | 329,821 |
| Receivables | 318,394 | 261,365 | 251,891 | 238,338 | 230,250 |
| Inventories | 468,161 | 475,775 | 457,393 | 429,831 | 384,143 |
| Other current assets | 71,760 | 74,036 | 83,646 | 62,875 | 60,340 |
| TOTAL | $2,241,110 | $2,207,144 | $2,050,029 | $1,458,820 | $1,352,788 |
| Non-Current Assets | |||||
| PPE Net | 895,392 | 896,700 | 878,624 | 851,097 | 824,013 |
| Investments And Advances | 313,599 | 385,785 | 416,304 | 482,036 | 533,628 |
| Intangibles | 706,941 | 714,549 | 727,996 | 735,604 | 743,211 |
| Other Non-Current Assets | 439,675 | 428,947 | 507,744 | 492,408 | 484,967 |
| TOTAL | $2,355,607 | $2,425,981 | $2,530,668 | $2,561,145 | $2,585,819 |
| Total Assets | $4,596,717 | $4,633,125 | $4,580,697 | $4,019,965 | $3,938,607 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 365,326 | 360,949 | N/A | N/A | 22,495 |
| Accounts payable and accrued liabilities | 408,145 | 455,569 | 417,529 | 374,303 | 317,711 |
| TOTAL | $773,471 | $816,518 | $417,529 | $374,303 | $340,206 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,016,243 | 1,007,944 | 1,349,606 | 850,083 | 829,314 |
| TOTAL | $1,016,243 | $1,007,944 | $1,349,606 | $850,083 | $829,314 |
| Total Liabilities | $1,789,714 | $1,824,462 | $1,767,135 | $1,224,386 | $1,169,520 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 176,713 | 176,072 | 175,621 | 175,268 | 174,490 |
| Common Shares | 177 | 176 | 176 | 175 | 173 |
| Retained earnings | -1,661,063 | -1,637,548 | -1,586,156 | -1,573,629 | -1,536,796 |
| Other shareholders' equity | -42,562 | -37,185 | -35,907 | -28,947 | -9,083 |
| TOTAL | $2,807,003 | $2,808,663 | $2,813,562 | $2,795,579 | $2,769,087 |
| Total Liabilities And Equity | $4,596,717 | $4,633,125 | $4,580,697 | $4,019,965 | $3,938,607 |